46 Biggest Movers From Yesterday
Gainers
Valneva SE (NASDAQ: VALN) shares surged 39.8% to close at $39.21 on Monday after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.
34 Stocks Moving In Monday’s Mid-Day Session
Gainers
Valneva SE (NASDAQ: VALN) shares jumped 34.6% to $37.75 after the company reported VLA2001 met both co-primary endpoints in the Phase 3 pivotal trial Cov-Compare.
Biogen’s Antisense Candidate Flunks In Late-Stage Neurodegenerative Disorder Trial
Biogen Inc (NASDAQ:BIIB) has announced topline results from its Phase 3 VALOR study of tofersen (BIIB067), an investigational antisense drug for…
Morgan Stanley Maintains Underweight on Ionis Pharmaceuticals, Lowers Price Target to $31
Morgan Stanley analyst David Lebowitz maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Underweight and lowers the price target from $33 to $31.
The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 30)
The Daily Biotech Pulse: AbbVie’s Migraine Drug OK’d By FDA, Amicus Spins Off Gene Therapy Business, Geovax In-Licenses Cancer Drug
Here's a roundup of top developments in the biotech space over the last 24 hours.
Click here for accessing Benzinga's FDA Calendar
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Sept. 28)
PTC Therapeutics’ Waylivra Scores Approval In Brazil For Genetic Disorder
The Brazilian Health Regulatory Agency has approved PTC Therapeutics Inc’s (NASDAQ:PTCT) Waylivra (volanesorsen) as the first treatment for familial chylomicronemia syndrome…
BMO Capital Maintains Outperform on Ionis Pharmaceuticals, Lowers Price Target to $68
BMO Capital analyst Gary Nachman maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Outperform and lowers the price target from $70 to $68.
SVB Leerink Maintains Market Perform on Ionis Pharmaceuticals, Lowers Price Target to $38
SVB Leerink analyst Mani Foroohar maintains Ionis Pharmaceuticals (NASDAQ:IONS) with a Market Perform and lowers the price target from $41 to $38.